SWOT Analysis for Heron Therapeutics Inc

Annual Profit Growth higher than Sector Profit Growth
PEG lower than Industry PEG
Efficient in managing Assets to generate Profits - ROA improving since last 2 year
Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years
Annual Net Profits improving for last 2 years
Stock with Low PE (PE < = 10)

Companies with growing costs YoY for long term projects
Bearish Stocks - Stocks with Medium to Low Trendlyne Momentum Score
Stocks with Expensive Valuations according to the Trendlyne Valuation Score
Highest fall from 52 Week High
Top Losers
Low Piotroski Score : Companies with weak financials
Declining Net Cash Flow : Companies not able to generate net cash
Book Value Per Share deteriorating for last 2 years
Weak performer : Stock lost more than 20% in 1 month
Weak Momentum: Price below Short, Medium and Long Term Averages
Declining profits every quarter for the past 2 quarters
Profit to Loss Companies
Declining Revenue every quarter for the past 2 quarters
RSI indicating price weakness
Top Losers
Stocks Underperforming their Industry Price Change in the Quarter